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A new fetal RHD genotyping test: Costs and
benefits of mass testing to target antenatal
anti-D prophylaxis in England and Wales
Ala Szczepura*, Leeza Osipenko, Karoline Freeman
Abstract
Background: Postnatal and antenatal anti-D prophylaxis have dramatically reduced maternal sensitisations and
cases of rhesus disease in babies born to women with RhD negative blood group. Recent scientific advances mean
that non-invasive prenatal diagnosis (NIPD), based on the presence of cell-free fetal DNA in maternal plasma, could
be used to target prophylaxis on “at risk” pregnancies where the fetus is RhD positive. This paper provides the first
assessment of cost-effectiveness of NIPD-targeted prophylaxis compared to current policies.
Methods: We conducted an economic analysis of NIPD implementation in England and Wales. Two scenarios were
considered. Scenario 1 assumed that NIPD will be only used to target antenatal prophylaxis with serology tests
continuing to direct post-delivery prophylaxis. In Scenario 2, NIPD would also displace postnatal serology testing if
an RhD negative fetus was identified. Costs were estimated from the provider’s perspective for both scenarios
together with a threshold royalty fee per test. Incremental costs were compared with clinical implications.
Results: The basic cost of an NIPD in-house test is £16.25 per sample (excluding royalty fee). The two-dose
antenatal prophylaxis policy recommended by NICE is estimated to cost the NHS £3.37 million each year. The
estimated threshold royalty fee is £2.18 and £8.83 for Scenarios 1 and 2 respectively. At a £2.00 royalty fee, mass
NIPD testing would produce no saving for Scenario 1 and £507,154 per annum for Scenario 2. Incremental cost-
effectiveness analysis indicates that, at a test sensitivity of 99.7% and this royalty fee, NIPD testing in Scenario 2 will
generate one additional sensitisation for every £9,190 saved. If a single-dose prophylaxis policy were implemented
nationally, as recently recommended by NICE, Scenario 2 savings would fall.
Conclusions: Currently, NIPD testing to target anti-D prophylaxis is unlikely to be sufficiently cost-effective to
warrant its large scale introduction in England and Wales. Only minor savings are calculated and, balanced against
this, the predicted increase in maternal sensitisations may be unacceptably high. Reliability of NIPD assays still
needs to be demonstrated rigorously in different ethnic minority populations. First trimester testing is unlikely to
alter this picture significantly although other emerging technologies may.
Background
In white Caucasian populations about 10% of all preg-
nancies involve a mother with rhesus (Rh) D negative
blood group and an RhD positive fetus, potentially
placing the mother at risk of sensitisation and future
babies at risk of haemolytic disease of the fetus and
newborn. Anti-D prophylaxis (anti-D IgG) can be
given to prevent a woman producing antibodies
against fetal RhD-positive blood cells and becoming
sensitised. Prophylaxis following delivery was intro-
duced in the 1960s, with a blood cord serology test
used to identify the baby’s RhD status. This dramati-
cally reduced maternal sensitisations and cases of rhe-
sus disease in babies [1]. In the mid-1990s, routine
antenatal anti-D prophylaxis (RAADP) was first used.
This was reported to further reduce sensitisation rates
(from 1.2% for the earlier policy to 0.28%) [2], with
RAADP stated to be 98.4-99% effective [3]. In 2002,
the National Institute for Health and Clinical Excel-
lence (NICE) published guidelines for the UK, recom-
mending two doses (500iu each) of anti-D IgG at
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weeks 28 and 34 of gestation as effective and cost-
effective [1]. Figures indicate that 90% of hospitals in
England and Wales comply with these guidelines, with
90% of the target population reported to receive the
first dose of anti-D IgG and up to 87% the second
dose [4,5]. In 2008, updated NICE guidance stated
that a single dose of anti-D (1500iu) between weeks
28 and 30 would also be cost-effective [6]. However,
with both RAADP policies, the 40% of RhD negative
women whose fetus is also RhD negative will receive
antenatal prophylaxis unnecessarily [1].
Non-invasive prenatal diagnosis (NIPD) of fetal RHD
blood group is based on the presence of cell-free fetal
DNA in maternal plasma [7-10]. Fetal RHD genotyping
of this material has the potential to enable antenatal
prophylaxis targeted at the 60% of pregnancies with an
RhD positive fetus, thereby saving anti-D costs. NIPD
test accuracy figures in the range 94.8% - 100% have
been reported [8,9,11-14], although studies exhibit cer-
tain shortcomings [15]. By 2007, many European coun-
tries had introduced NIPD testing for the small number
of sensitised women in order to identify high risk preg-
nancies (fetus RhD positive) [10,14,16]. Approximately
250-300 sensitised women in England and Wales now
undergo RhD NIPD tests annually. In such cases the
NIPD test offers the clinical advantage of avoiding an
invasive procedure such as amniocentesis with its asso-
ciated risk of fetal loss [17], as well as possible cost
savings.
Several authors have recently recommended a wider
roll-out of NIPD testing to the remaining, non-sensitised
pregnancies [10,14,16], with suggestions that this will be
cost saving [16,18]. Such an approach would extend
testing to a significantly larger population. Approxi-
mately 16% of white women are RhD negative; RhD
negativity in other ethnic groups is lower; South Asians
(5.5% - 10.9%), West Africans (5%), Chinese (<1%)
[19,20]. Extension of NIPD testing to this larger popula-
tion (approximately 93,000 pregnancies annually in Eng-
land and Wales [21]) is not feasible with the low
throughput and labour intensive processes used for test-
ing samples from sensitised women [22]. Mass testing
will require an accurate automated laboratory proce-
dure, similar to that recently reported which has a test
sensitivity of 99.7% [16]. NIPD testing is not able to
identify the degree to which a woman is prone to sensi-
tisation because this is governed by several factors in
addition to fetal RHD status [23].
To date the costs and implications of large scale NIPD
testing to target antenatal prophylaxis have not been
determined. The aim of the present study was to esti-
mate the cost savings (if any) in England and Wales for
two implementation strategies compared to the current
two-dose RAADP programme (and a possible future
single-dose policy). The research was undertaken as part
of the SAFE Network of Excellence funded by the
European Commission [24].
Methods
Design of the study
Costs were estimated for the following strategies for
implementing NIPD:
• Scenario 1: Assumed that all RhD negative women
will routinely receive an NIPD test and that antena-
tal prophylaxis will be withheld if an RhD negative
fetus is identified; post-delivery testing and postnatal
prophylaxis assumed to be unaffected.
• Scenario 2: Assumed that, in addition to Scenario
1, post-delivery blood cord serology and associated
Kleihauer test (to measure the amount of fetal hae-
moglobin transferred to the mother’s bloodstream
to determine anti-D IgG dose required) will be
withheld if NIPD has identified an RhD negative
fetus.
The cost analysis was undertaken from the perspec-
tive of the National Health Service (NHS healthcare
provider) in England and Wales. It was assumed that
NIPD testing could be fitted into current antenatal
care without increasing the number of prenatal visits,
so costs such as patient time, travel etc. were not
expected to differ significantly. A primary costing
approach and financial modelling were used to esti-
mate the incremental cost of moving from the status
quo (RAADP) to one of the two scenarios. The conse-
quences of implementing each scenario were also esti-
mated, based on a range of parameters. All costs are
expressed in 2009 prices.
Test costs
A unit test cost (base case) was determined for NIPD.
Laboratory resource use data were collected in the
International Blood Group Reference Laboratory, Bristol,
UK [16]. In-house laboratory processing costs were
based on a protocol developed and standardised in sev-
eral European laboratories [25]. Equipment costs,
including plasma preparation, DNA extraction (MDX
robot from Qiagen or similar) and DNA sequencing
(7900 SD from Applied Biosystems or similar) were dis-
counted over five years and converted to an annual
equivalent cost; associated annual maintenance contract
costs were added. A maximum annual throughput of
44,000 samples per set of equipment was assumed. At
current RAADP uptake levels in England and Wales,
two sets of equipment would be required; if all RhD
negative pregnancies were to be tested, a third set of
equipment would be needed. Consumable list prices for
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primers, probes (Exon 5 and 7), controls, reagents and
other items were discounted by 20% to allow for bulk
purchase. Direct staff time (excluding non-contact time)
included employer on-costs (NI and Superannuation) at
22% [26]. Interpretation of results was assumed to be
carried out by an automated Hematos system [27].
Laboratory overheads were assumed to be similar to
other tests at the study site. Allowance was made for
inconclusive NIPD results requiring re-test rates
between 1.4% and 3% [10,16,28]. Re-test costs assumed
no further phlebotomy cost with some original blood
sample preserved for re-tests. Sample collection costs
included consumables and staff time [29]. The cost of
sample transport was based on local transport system
prices. Postnatal serology test, Kleihauer test and asso-
ciated phlebotomy costs were based on local prices
(West Midlands).
An in-house testing service might also incur a royalty
payment (fetal DNA presence in maternal blood: United
States Patent 6258540). This has not yet been negotiated
in any country. An alternative to an in-house test would
be use of a commercial kit (Institut de Biotechnologies
Jacques Boy, France) which has recently been CE
marked for use in Europe [30]. The price of the kit
includes a royalty fee, controls, primers, probes (Exons
7, 10 and IRV2) but excludes other materials (MDX kit,
LG tips, SML tips, Eton, AW1, buffer, detergent). A unit
test cost was similarly calculated for NIPD testing using
this commercial kit.
Cost of Status Quo Antenatal Anti-D Prophylaxis
The cost of current anti-D prophylaxis was estimated
based on available anti-D IgG products, their UK market
share, and the proportion of women receiving prophy-
laxis. The cost of administering anti-D was based on
published estimates [31].
Financial Benefits of Implementation Scenarios 1 and 2
The incremental cost of moving from the status quo
(universal anti-D prophylaxis) to NIPD targeted prophy-
laxis was estimated. In both scenarios it was assumed
that 80% of all RhD negative women will be tested and,
as a result, 62% will receive antenatal anti-D; the latter
figure allows for the false positive rate (2%) for RhD
NIPD tests [16]. A threshold analysis to identify the cir-
cumstances under which NIPD might be considered
economically attractive compared to RAADP was under-
taken for each scenario. For in-house tests, two key cost
drivers were identified (royalty fee and price of anti-D
IgG). Royalty fees, which are unknown, were varied
between zero and an upper figure estimated from com-
mercial kit prices; anti-D IgG costs were varied based
on historical price variations and expert opinion about
future costs.
Clinical Consequences and Cost-effectiveness of
Implementation Scenarios 1 and 2
The consequences of implementing scenarios 1 and 2
were estimated. These included consideration of para-
meters such as: false negative and false positive rates;
additional sensitisations; and risk of infection from anti-
D blood product. Since definitive prospective trial out-
comes data is not available for all parameters, some
drew on international experts and a review of the litera-
ture [13,15]. The incremental cost per change in effec-
tiveness (increased number of sensitisations) was
estimated for different test sensitivities.
Results
Test costs
Table 1 provides a breakdown of NIPD unit testing cost
for a national programme using in-house tests. This
basic cost of £16.25 per patient sample represents a
minimum because it excludes any royalty fee.
Use of a commercial kit is calculated to increase test-
ing costs to £46.50 per patient sample. If, as indicated
with this kit, a second confirmatory test is required later
in pregnancy for all RhD negative results, this would
increase costs further to an average of more than £65
per patient. Other test costs were estimated at: postnatal
serology test (£3.78); Kleihauer test (£2.87); and asso-
ciated phlebotomy cost (£3).
Cost of Status Quo Antenatal Anti-D Prophylaxis
Table 2 presents a breakdown of the annual cost of
RAADP in England and Wales (£3.37 million). This is
based on the market share for different manufacturers’
products, current prophylaxis protocol (500iu BPL;
1250iu Baxter), and a cost of administering prophylaxis
Table 1 Base Case: Unit Test Cost1 (In-House Laboratory
Protocol)
Item Cost per sample (£)
Blood sampling (phlebotomy) 3.002
Sample transport & registration 1.103
Laboratory consumables 4.224
Laboratory equipment 1.025
Laboratory labour 2.07
Result reporting 1.00
Re-tests 0.29
Laboratory overheads 3.55
Unit Test Cost 16.25
1 Figures excluding any royalty fee.
2 See [29].
3 Based on current charges in West Midlands for mailing 4 samples. Figure
will be lower if existing transportation system used; and higher if < 4 samples
mailed.
4 Based on 88 samples per run, includes 20% discount for bulk purchase.
5 Assumes 44,000 samples processed annually per set of equipment.
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at £5 per dose [31]. If a single-dose policy (1500iu) were
to become widespread (NICE 2008), this would reduce
annual RAADP costs to £2.88 million assuming similar
uptake levels.
Financial Benefits of Implementation Scenarios 1 and 2
Figure 1 presents the annual cost of Scenarios 1 and 2
at varying unit test costs compared to the annual cost of
RAADP (£3.37 million). For in-house tests, threshold
analysis shows that Scenario 1 will be less expensive
than current RAADP (cost saving) as long as the total
NIPD testing cost is below £18.43 per woman. Scenario
1 is predicted to produce a national saving of 5%
(£162,258) for in-house tests with a zero royalty fee
(£16.25); and virtually no cost saving if the royalty fee is
£2.00 (threshold fee is £2.18 per sample). If a single-
dose policy were to be introduced, the threshold cost
would fall to £15.95 per sample, indicating that NIPD
will not be cost saving even at a zero royalty fee. In Sce-
nario 2, there are potentially greater savings because
NIPD now displaces post-natal testing as well as redu-
cing antenatal prophylaxis. In this case, at a £2.00
royalty fee the annual saving predicted for the current
two-dose policy rises to 15% of annual RAADP costs
(£507,154) with a threshold royalty fee of £8.83. Once
again, if a single-dose policy were to be universally
accepted annual savings would fall to £321,993 driving
the threshold royalty fee to £6.35. Although laboratory
throughput was found to have minimal impact on sce-
nario costs, changes in anti-D IgG prices could influence
whether scenarios generate cost savings. For Scenario 1,
at zero royalty fee, as long as the average price of anti-D
IgG per case is above £28.67, implementation of NIPD
remains financially favourable. For Scenario 2, the com-
parable figure is £39.70. Anti-D IgG prices have
remained relatively stable over the last 6 years and are
not expected to show significant changes in the mid-
term [Dr E Gascoigne, Bio Products Laboratory, UK,
personal communication].
Figure 1 shows that the unit test cost of the commer-
cial kit (£46.50) cuts the line for both scenarios signifi-
cantly above the cost of RAADP and therefore is not
financially attractive, even if a repeat test were not
required later in pregnancy.
Clinical Consequences and Cost-effectiveness of
Implementation Scenarios 1 and 2
Although annual cost savings of up to £162,258 (Sce-
nario 1) and £656,720 (Scenario 2) are potentially feasi-
ble with zero royalty fee, any financial benefit should be
considered against possible clinical consequences follow-
ing NIPD introduction. For example, if an RhD positive
fetus is misdiagnosed as RhD negative, due to sub-opti-
mal RhD NIPD test performance [8,9,11-14], there will
be an increased risk of sensitisation (0.9-1.5%) due to
antenatal prophylaxis being withheld in these cases
[32,33]. Table 3 shows the number of additional sensiti-
sations predicted in England and Wales at different
NIPD test sensitivity levels for a two-dose policy. In Sce-
nario 1, women who miss their antenatal prophylaxis
will still receive postnatal prophylaxis so there will be
no further added risk of sensitisation. However, in
Table 2 Annual Cost for Routine Antenatal Anti-D Prophylaxis (England & Wales)
Product Market
Share (%)
1st Dose
(Injections/Year)
2nd Dose
(Injections/Year)
Cost per
Dose (£)
Total Cost for
RAADP1 (£/year)
D-Gam (BPL) 2 × 500 IU 48 35,896 34,731 19.50 2 1,730,362
D-Gam (BPL) 1 × 1500 IU 1 748 N/A 33.50 28,791
Rhophylac (CSL) 1 × 1500 IU 40 29,913 N/A 33.50 1,151,654
Partobulin (Baxter) 2 × 1250 IU 11 8,226 7,959 23.35 457,236
Total 74,783 42,691 3,368,044
1 Based on an estimated 74,783 women receiving routine antenatal prophylaxis.
2 Bulk of BPL product used in NHS hospitals purchased at price of £ 19.50/500iu [Dr E Gascoigne, Bio Products Laboratory (BPL), UK, personal communication].
BPL list price of £27/500iu dose is only applicable to private hospitals.
Figure 1 Annual Cost of Scenarios 1 and 2 for Different NIPD
Unit Test Costs vs. Cost of Current RAADP Policy.
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Scenario 2 (where postnatal serology tests are elimi-
nated) these same women will now not receive anti-D
post-delivery. The risk of sensitisation in such cases
rises significantly to 13.2% [3]. Table 3 shows that, in
Scenario 2, if sensitivity falls below 95% an additional
744 women could become sensitised in England and
Wales each year.
The figures for different test sensitivities are compared
with the predicted incremental cost saving in the final
columns, both with a zero royalty fee and a fee of £2.00
per sample. If mass testing is introduced as described in
Scenario 1 and a test sensitivity of 99.7% can be
achieved [16], this will mean that £54,086 can be saved
at the price of each additional sensitisation, as long as a
zero royalty fee applies. If a fee of £2.00 per sample is
incurred, similar to that negotiated for Q-PCR by the
NHS at £2.70 per test single marker [17] then this figure
falls to £4,231 saved per additional sensitisation. For
Scenario 2, similar figures are a saving of £15,636 or
£12,075 per additional sensitisation respectively. If we
include the extra cost incurred for management of sen-
sitisations, most recently estimated at an average £2,885
per person [19], Scenario 2 will generate one additional
sensitisation for every £9,190 saved at this royalty fee.
Discussion
Management of non-sensitised RhD negative pregnan-
cies has become considerably more effective over time
with the sequential introduction of post-delivery and
antenatal anti-D prophylaxis [6]. Residual RhD sensitisa-
tions still occur, mainly due to poor prophylaxis imple-
mentation, administration errors and sub-optimal
patient compliance [5,19,34]. Advocates of mass RhD
NIPD testing therefore focus on the potential for gener-
ating net cost savings although this is not quantified
[16,18].
The cost analysis presented in this paper shows that
the net financial benefit of implementing mass NIPD
testing as an add-on using in-house tests (while main-
taining current postnatal testing) will be negligible in
England and Wales. The level of royalty fee negotiated
will be a major influence on this with zero saving pre-
dicted above a fee of £2.18 per test. If antenatal NIPD
were to also displace postnatal testing, higher net sav-
ings could be realised and the royalty fee might rise to
nearly £9 per test before these disappear. Use of a com-
mercial kit, such as that currently being marketed in
Europe [30] would make NIPD more expensive in both
implementation scenarios. Furthermore, if single-dose
prophylaxis, now recommended as equally effective by
NICE [6], were to become widespread only the second
scenario (displacing postnatal testing) would produce a
net saving.
Our analysis also indicates that NIPD implementation
is unlikely to produce important clinical benefits. The
number of sensitisations will not fall appreciably and in
fact might rise if NIPD test sensitivity is below 99.9%.
This is especially true for the scenario in which postna-
tal blood cord serology is eliminated in order to maxi-
mise any net cost saving. Introduction of NIPD typing
must also meet the needs of testing in a diverse popula-
tion [35]. In the UK, the Race Relations Amendment
Act 2000 lays a statutory duty upon the NHS to con-
sider the implications of any new policy on racial equal-
ity [36]. In white Caucasians, the most frequent RhD
negative genotype is caused by an RHD deletion, while
Table 3 Additional Sensitisations (England & Wales) for Different Test Sensitivities
Additional Sensitisations/Year1 Incremental Cost-Effectiveness Ratio 2
RhD NIPD sensitivity 3 Scenario 1 4 Scenario 2 5 Scenario 1 (£/sensitisation) Scenario 2 (£/sensitisation)
94.8% 6 54 744 3,005 (235) 883 (682)
96.0% 42 573 3,863 (302) 1,146 (885)
97.0% 31 430 5,234 (409) 1,527 (1,179)
98.0% 21 283 7,727 (604) 2,320 (1,793)
98.4% 17 226 9,545 (747) 2,906 (2,244)
99.0% 10 141 16,226 (1,269) 4,658 (3,597)
99.2% 8 113 20,282 (1,586) 5,812 (4,488)
99.4% 6 85 27,043 (2,115) 7,726 (5,966)
99.7% 3 42 54,086 (4,231) 15,636 (12,075)
99.9% 1 14 162,258 (12,692) 46,908 (36,225)
1 Assuming current serology is 100% accurate.
2 Incremental cost i.e. £ sterling saved per additional sensitisation produced. Figures in brackets ( ), assumes royalty fee negotiated at £2.00 per test.
3 Sensitivity range based on values reported in literature [13,16].
4 Antenatal anti-D prophylaxis directed by RhD NIPD results & postnatal anti-D by serology (1.3% risk) [2].
5 Postnatal anti-D prophylaxis based on RhD NIPD antenatal result (13.2% risk) [3].
6 Meta-analysis figure for diagnostic accuracy [13].
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in Black Africans and South Asians other variants exist
which can result in mistyping [37]. There has been a
recent call for careful consideration of patients’ ethnic
background by obstetricians [38]. Antenatal prophylaxis
has been reported to be equally effective, and also more
cost-effective, in ethnic minority populations in the UK
and elsewhere [19,23,39,40]. However, to date NIPD
assays have primarily been validated in white Caucasian
populations and their reliability in ethnic minority popu-
lations still has to be demonstrated [41]. Due to the
absence of a ‘gold standard’ comparator, it is not possi-
ble to establish the absolute accuracy of the serology
test, although since the test is performed manually it
will be prone to some human error. Thus, even in sce-
nario 1, sensitisations may occur because of inaccuracy
in the postnatal serology test. Two recent studies have
suggested that RhD NIPD may provide more accurate
results than postnatal serology, both by minimising
human error and by helping to detect D variants and
weak D newborns [14,28].
Based on our findings it is difficult to argue that NIPD
targeted antenatal prophylaxis will be sufficiently cost-
effective to warrant its large scale introduction.
Increased magnitude of savings will be at the expense of
additional sensitisations. Even the maximum amount of
£9,190 saved per additional sensitisation is much lower
than the figure of £15,903 - £17,668 judged acceptable
for avoiding a sensitisation by NICE [42].
However, if NIPD testing could be carried out earlier
in pregnancy cost-effectiveness might be improved. For
example, adherence to prophylaxis guidelines for ‘high
risk’ antenatal events might be improved if women are
identified as carrying an RhD positive child early in
their pregnancy [43,44]. Balanced against this is the fact
that NIPD test accuracy is known to deteriorate at
lower gestational age [45-47]. The accuracy of mass test-
ing in early pregnancy is uncertain. A large scale UK
trial of NIPD testing in the first trimester of pregnancy
has still to report [Dr. Kirstin Finning, National Blood
Service, Bristol, UK, personal communication]. However,
a US company which has recently launched a fetal RHD
genotyping test for use in first-trimester pregnancies
reports a sensitivity of 97.2% [48].
During the development of the original 2002 NICE
guidelines, questions were raised about the safety of
anti-D IgG because of isolated cases of hepatitis C infec-
tion in the early 1990’s [49,50]. Avoidance of unneces-
sary use of anti-D has therefore been suggested as a
‘soft benefit’ for NIPD even though anti-D continues to
be judged safe for routine antenatal use by NICE [1,6].
Modern processes make it among the lowest-risk biolo-
gical products in use [51], especially in combination
with avoidance of high risk plasma donors [52-54]. A
second linked argument is that NIPD might improve
prophylaxis coverage [4]. Some authors have suggested
that low uptake might be linked to anxiety about anti-D
blood products [4,5,55]. At the same time, it is recog-
nised that poor antenatal attendance, knowledge that
the father is RhD negative, or certainty that this is a
woman’s last pregnancy influence uptake [19]. Such fac-
tors would be unaffected by introduction of NIPD.
A final advantage put forward is linked to anti-D
supply. In England and Wales, where anti-D IgG is pro-
duced using plasma purchased from the USA, there
have been no supply problems. However, in countries
such as the Netherlands where in-country sourcing
requires the purposeful hyperimmunisation of volun-
teers, decreased use of anti-D has been viewed as an
ethical benefit in its own right [56]. Scientists are cur-
rently working on the development of recombinant anti-
D IgG as a replacement for human plasma products
[57]. Although there is no completely satisfactory
product on the market [58], a phase 2 clinical trial has
recently commenced [59]. In future, this has the poten-
tial to address these concerns [60,61]. If, as is likely, the
final recombinant product is more expensive than the
human product then NIPD would become financially
more attractive by generating greater anti-D savings.
The main limitation in the present study is uncer-
tainty over the level of royalty fee for in-house NIPD
tests. The speed of development and diffusion of recom-
binant anti-D IgG may also affect the conclusion drawn,
but this is difficult to estimate without information on
the eventual cost of this product. Further new technolo-
gies which might influence cost-effectiveness include
NIPD markers for conditions such as haemoglobinopa-
thies or Trisomy 21 (Down’s syndrome) which appear to
be nearing final development [62-66]. If a battery of
markers, including fetal RHD status, were combined in a
single NIPD test then this would reduce costs through
economies of scale in common processes such as DNA
extraction and amplification. Finally, our economic ana-
lysis, which only considered England and Wales, may be
less applicable in other countries. For example, in some
European countries there is no policy of routine antena-
tal prophylaxis although this is now being considered
[67,68]. In such cases, the introduction of targeted pro-
phylaxis underpinned by RhD NIPD testing might offer
similar clinical benefit to introduction of RAADP at a
potentially acceptable cost.
Conclusion
Our analysis does not support routine implementation
of RhD NIPD testing in England and Wales at present
for non-sensitised pregnancies. Annual savings will be
relatively small and balanced against this increased
maternal sensitisations may be unacceptably high. First
trimester testing is unlikely to alter this picture
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significantly although other emerging technologies may.
There is also a need to demonstrate the reliability of
assays in different ethnic minority populations.
Acknowledgements
We would like to thank the following for providing us with data and clinical
information: Prof. Tobias Legler, Universitätsmedizin Göttingen, Germany; Dr.
Kirstin Finning, National Blood Service, Bristol, UK; Dr. Antonio Borrell,
Hospital Clinic, Barcelona, Spain; Carl Holland, Pathology Service, University
Hospitals Coventry and Warwickshire NHS Trust, UK; Dr. Edwin Massey,
National Blood Service, Bristol, UK; Prof. Peter Soothill, University of Bristol,
UK; Dr. Geoff Daniels, National Blood Service, Bristol, UK; Prof Stan Urbaniak,
Academic Transfusion Medicine Unit, University of Aberdeen, UK; and Dr.
Ernie Gascoigne, Bio Products Laboratory, UK. We also would like to thank all
SAFE partners who helped us collect necessary data for the project and Dr.
Stavros Petrou, National Perinatal Epidemiology Unit, Oxford, for valuable
feedback.
This work was supported by the European Commission funds allocated to
the SAFE Network of Excellence under the 6th Framework. Project Number:
LSHB-CT-2004-503243.
Ethics Approval
This study did not require ethics approval.
Authors’ contributions
AS, LO and KF conceived the idea for the study. LO obtained the data and
completed the analysis. AS and LO wrote the manuscript which was
reviewed by all authors. All authors had full access to all data in the study
and can take responsibility for the integrity of the data and the accuracy of
the analysis. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 11 October 2010 Accepted: 18 January 2011
Published: 18 January 2011
References
1. NICE: The clinical effectiveness and cost effectiveness of routine anti-D
prophylaxis for RhD-negative women in pregnancy. Technology appraisals
TA41 2002.
2. Mayne S, Parker JH, Harden TA, Dodds SD, Beale JA: Rate of RhD
sensitisation before and after implementation of a community based
antenatal prophylaxis programme. BMJ 1997, 315(7122):1588.
3. Bowman J: Thirty-five years of Rh prophylaxis. Transfusion 2003,
43(12):1661-1666.
4. Chaffe B, Ford J, Bills V: Routine antenatal anti-D prophylaxis and
patient compliance with the two-dose regimen. Transfus Med 2007,
17(5):399-403.
5. MacKenzie IZ, Findlay J, Thompson K, Roseman F: Compliance with routine
antenatal rhesus D prophylaxis and the impact on sensitisations:
observations over 14 years. BJOG 2006, 113(7):839-843.
6. NICE: Pregnancy - routine anti-D prophylaxis for rhesus negative women
(review of TA41). Technology appraisals TA156 2008.
7. Lo YM, Tein MS, Lau TK, Haines CJ, Leung TN, Poon PM, Wainscoat JS,
Johnson PJ, Chang AM, Hjelm NM: Quantitative analysis of fetal DNA in
maternal plasma and serum: implications for noninvasive prenatal
diagnosis. Am J Hum Genet 1998, 62(4):768-775.
8. Hromadnikova I, Vechetova L, Vesela K, Benesova B, Doucha J, Kulovany E,
Vlk R: Non-invasive fetal RHD exon 7 and exon 10 genotyping using
real-time PCR testing of fetal DNA in maternal plasma. Fetal Diagn Ther
2005, 20(4):275-280.
9. Finning KM, Martin PG, Soothill PW, Avent ND: Prediction of fetal D status
from maternal plasma: introduction of a new noninvasive fetal RHD
genotyping service. Transfusion 2002, 42(8):1079-1085.
10. van der Schoot CE, Hahn S, Chitty LS: Non-invasive prenatal diagnosis and
determination of fetal Rh status. Semin Fetal Neonatal Med 2008,
13(2):63-68.
11. Rouillac-Le Sciellour C, Puillandre P, Gillot R, Baulard C, Metral S, Le Van
Kim C, Cartron JP, Colin Y, Brossard Y: Large-scale pre-diagnosis study of
fetal RHD genotyping by PCR on plasma DNA from RhD-negative
pregnant women. Mol Diagn 2004, 8(1):23-31.
12. van der Schoot C: Prenatal fetal RhD blood group typing to enhance
efficiency of antenatal anti-D immunoprophylaxis in RhD negative
pregnant women. Final Report Health Care Efficiency Research Programme
2005.
13. Geifman-Holtzman O, Grotegut CA, Gaughan JP: Diagnostic accuracy of
noninvasive fetal Rh genotyping from maternal blood-a meta-analysis.
Am J Obstet Gynecol 2006, 195(4):1163-1173.
14. Minon JM, Gerard C, Senterre JM, Schaaps JP, Foidart JM: Routine fetal
RHD genotyping with maternal plasma: a four-year experience in
Belgium. Transfusion 2008, 48(2):373-381.
15. Freeman K, Szczepura A, Osipenko L: Non-invasive fetal RHD genotyping
tests: a systematic review of the quality of reporting of diagnostic
accuracy in published studies. Eur J Obstet Gynecol Reprod Biol 2009,
142(2):91-98.
16. Finning K, Martin P, Summers J, Massey E, Poole G, Daniels G: Effect of
high throughput RHD typing of fetal DNA in maternal plasma on use of
anti-RhD immunoglobulin in RhD negative pregnant women:
prospective feasibility study. BMJ 2008, 336(7648):816-818.
17. Grimshaw GM, Szczepura A, Hulten M, MacDonald F, Nevin NC, Sutton F,
Dhanjal S: Evaluation of molecular tests for prenatal diagnosis of
chromosome abnormalities. Health Technol Assess 2003, 7(10):1-146.
18. van der Schoot CE, Soussan AA, Koelewijn J, Bonsel G, Paget-Christiaens LG,
de Haas M: Non-invasive antenatal RHD typing. Transfus Clin Biol 2006,
13(1-2):53-57.
19. Pilgrim H, Lloyd-Jones M, Rees A: Routine antenatal anti-D prophylaxis for
RhD-negative women: a systematic review and economic evaluation.
Health Technol Assess 2009, 13(10):1-103, iii, ix-xi.
20. Szczepura OL A, Freeman K: Non-Invasive Prenatal Diagnosis (NIPD): Fetal
RHD Genotype: Early-HTA Report. SAFE NoE 2007.
21. UK National Statistics. [http://www.statistics.gov.uk/].
22. Daniels G, Finning K, Martin P, Summers J: Fetal blood group genotyping:
present and future. Ann N Y Acad Sci 2006, 1075:88-95.
23. Contreras M: The prevention of Rh haemolytic disease of the fetus and
newborn–general background. Br J Obstet Gynaecol 1998, 105(Suppl
18):7-10.
24. Freeman K, Osipenko L, Clay D, Hyde J, Szczepura A: A Review of Evidence
on Non-invasive Prenatal Diagnosis (NIPD): Tests for Fetal RHD
Genotype. Workpackage 6, SAFE Network of Excellence Warwick Medical
School, UK; 2006.
25. Legler TJ, Liu Z, Mavrou A, Finning K, Hromadnikova I, Galbiati S, Meaney C,
Hulten MA, Crea F, Olsson ML, et al: Workshop report on the extraction of
foetal DNA from maternal plasma. Prenat Diagn 2007, 27(9):824-829.
26. The SiriusWeb Staff Costs Calculator. [http://www.siriusweb.leeds.ac.uk].
27. Hematos System Description. [http://www.savant.co.uk/product/hematos].
28. Muller SP, Bartels I, Stein W, Emons G, Gutensohn K, Kohler M, Legler TJ:
The determination of the fetal D status from maternal plasma for
decision making on Rh prophylaxis is feasible. Transfusion 2008,
48(11):2292-2301.
29. NHS Reference Costs. [http://www.dh.gov.uk/en/Publicationsandstatistics/
Publications/PublicationsPolicyAndGuidance/DH_082571].
30. Free DNA Fetal Kit® RhD. Kit de génotypage foetal RhD à partir d’ADN
foetal libre du sang maternel. [http://www.biotechjboy.com/
biologie_moleculaire/biologie_moleculaire.htm].
31. Chilcott J, Lloyd Jones M, Wight J, Forman K, Wray J, Beverley C,
Tappenden P: A review of the clinical effectiveness and cost-
effectiveness of routine anti-D prophylaxis for pregnant women who are
rhesus-negative. Health Technol Assess 2003, 7(4):iii-62.
32. Urbaniak SJ: The scientific basis of antenatal prophylaxis. Br J Obstet
Gynaecol 1998, 105(Suppl 18):11-18.
33. Tovey LA, Townley A, Stevenson BJ, Taverner J: The Yorkshire antenatal
anti-D immunoglobulin trial in primigravidae. Lancet 1983,
2(8344):244-246.
34. Wickham S: Midwives and anti-D. Enabling choice. Pract Midwife 2000,
3(10):11-12.
35. Machado IN, Castilho L, Pellegrino J Jr, Barini R: Fetal rhd genotyping from
maternal plasma in a population with a highly diverse ethnic
background. Rev Assoc Med Bras 2006, 52(4):232-235.
36. Szczepura A: Access to health care for ethnic minority populations.
Postgrad Med J 2005, 81(953):141-147.
Szczepura et al. BMC Pregnancy and Childbirth 2011, 11:5
http://www.biomedcentral.com/1471-2393/11/5
Page 7 of 8
37. Westhoff CM: The Rh blood group system in review: a new face for the
next decade. Transfusion 2004, 44(11):1663-1673.
38. Wang D, Lane C, Quillen K: Prevalence of RhD variants, confirmed by
molecular genotyping, in a multiethnic prenatal population. Am J Clin
Pathol 2010, 134(3):438-442.
39. Ali N, Anwar M, Bhatti F, Nadeem M, Nadeem A, Ali M: Frequency of ABO
and Rh blood groups in major ethnic groups and casts of Pakistan.
Pakistan J Med Sci 2005, 21:26-29.
40. Adams MM, Marks JS, Koplan JP: Cost implications of routine antenatal
administration of Rh immune globulin. Am J Obstet Gynecol 1984,
149(6):633-638.
41. Equality Act 2010. [http://www.equalities.gov.uk/equality_act_2010.aspx].
42. Chilcott J, Tappenden P, Lloyd Jones M, Wight J, Forman K, Wray J,
Beverley C: The economics of routine antenatal anti-D prophylaxis for
pregnant women who are rhesus negative. BJOG 2004, 111(9):903-907.
43. Koelewijn J: Detection and prevention of pregnancy immunisation. The
OPZI-study. Doctoral Thesis. University of Amsterdam 2009.
44. Kumpel BM: Efficacy of RhD monoclonal antibodies in clinical trials as
replacement therapy for prophylactic anti-D immunoglobulin: more
questions than answers. Vox Sang 2007, 93(2):99-111.
45. Clausen FB, Krog GR, Rieneck K, Nielsen LK, Lundquist R, Finning K,
Dickmeiss E, Hedegaard M, Dziegiel MH: Reliable test for prenatal
prediction of fetal RhD type using maternal plasma from RhD negative
women. Prenat Diagn 2005, 25(11):1040-1044.
46. Chan LY, Leung TN, Chan KC, Tai HL, Lau TK, Wong EM, Lo YM: Serial
analysis of fetal DNA concentrations in maternal plasma in late
pregnancy. Clin Chem 2003, 49(4):678-680.
47. Costa JM, Giovangrandi Y, Ernault P, Lohmann L, Nataf V, El Halali N,
Gautier E: Fetal RHD genotyping in maternal serum during the first
trimester of pregnancy. Br J Haematol 2002, 119(1):255-260.
48. SensiGene Fetal RHD Genotyping. [http://www.scmmlab.com/Home/
Health-Care-Professionals/Fetal-RHD-Genotyping].
49. Dittmann S, Roggendorf M, Durkop J, Wiese M, Lorbeer B, Deinhardt F:
Long-term persistence of hepatitis C virus antibodies in a single source
outbreak. J Hepatol 1991, 13(3):323-327.
50. Power JP, Lawlor E, Davidson F, Yap PL, Kenny-Walsh E, Whelton MJ,
Walsh TJ: Hepatitis C viraemia in recipients of Irish intravenous anti-D
immunoglobulin. Lancet 1994, 344(8930):1166-1167.
51. Burnouf T: Modern plasma fractionation. Transfus Med Rev 2007,
21(2):101-117.
52. Gregori L, Maring JA, MacAuley C, Dunston B, Rentsch M, Kempf C,
Rohwer RG: Partitioning of TSE infectivity during ethanol fractionation of
human plasma. Biologicals 2004, 32(1):1-10.
53. Farrugia A: vCJD donor deferral measures. Montreal. World Federation of
Haemophilia 2001.
54. Revised preventive measures to reduce the possible risk of transmission
of Creutzfeldt-Jakob disease (CJD) and variant Cruetzfeldt-Jakob disease
(vCJD) by blood and blood products. [http://www.fda.gov/ohrms/dockets/
ac/01/briefing/3796b1_03.pdf].
55. Wickham S: Rhogam: evidence from midwives. Midwifery Today Int Midwife
2000, , 53: 44-45.
56. Bonsel G, et al: Final Report Health Care Efficiency Research Programme.
ZonMw 2005.
57. Szczepura A, Osipenko L, Freeman K: Emerging technologies in the
management of RhD negative pregnant women. Workpackage 6, SAFE
Network of Excellence Warwick Medical School, UK; 2007.
58. Kumpel BM: Lessons learnt from many years of experience using anti-D
in humans for prevention of RhD immunization and haemolytic disease
of the fetus and newborn. Clin Exp Immunol 2008, 154(1):1-5.
59. Symphogen. Sym001 (anti-RhD). [http://www.symphogen.com/web/guest/
sym001].
60. Storry J: New technologies to replace current blood typing reagents.
Current Opinion in Hemotology 2007, 14(6):677-681.
61. Hirose TG, Mays DA: The safety of RhIG in the prevention of haemolytic
disease of the newborn. J Obstet Gynaecol 2007, 27(6):545-557.
62. Prenatal Diagnostics. [http://www.sequenom.com/Home/Products—
Services/Diagnostics/Prenatal-Diagnostics].
63. Lab Prepares Launch of Trisomy 21 Diagnostic Test. [http://www.
labmedica.com/lab_technology/articles/294730804/
lab_prepares_launch_of_trisomy_21_diagnostic_test.html].
64. Dhallan R, Guo X, Emche S, Damewood M, Bayliss P, Cronin M, Barry J,
Betz J, Franz K, Gold K, et al: A non-invasive test for prenatal diagnosis
based on fetal DNA present in maternal blood: a preliminary study.
Lancet 2007, 369(9560):474-481.
65. Lo YM, Lun FM, Chan KC, Tsui NB, Chong KC, Lau TK, Leung TY, Zee BC,
Cantor CR, Chiu RW: Digital PCR for the molecular detection of fetal
chromosomal aneuploidy. Proc Natl Acad Sci USA 2007,
104(32):13116-13121.
66. Maron JL, Bianchi DW: Prenatal diagnosis using cell-free nucleic acids in
maternal body fluids: a decade of progress. Am J Med Genet C Semin Med
Genet 2007, 145C(1):5-17.
67. Liumbruno GM, D’Alessandro A, Rea F, Piccinini V, Catalano L, Calizzani G,
Pupella S, Grazzini G: The role of antenatal immunoprophylaxis in the
prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus
2010, 8(1):8-16.
68. Velati C: A survey of the current use of anti-D immunoprophylaxis and
the incidence of haemolytic disease of the newborn in Italy. Blood
Transfus 2007, 5(1):7-14.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2393/11/5/prepub
doi:10.1186/1471-2393-11-5
Cite this article as: Szczepura et al.: A new fetal RHD genotyping test:
Costs and benefits of mass testing to target antenatal anti-D
prophylaxis in England and Wales. BMC Pregnancy and Childbirth 2011
11:5.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Szczepura et al. BMC Pregnancy and Childbirth 2011, 11:5
http://www.biomedcentral.com/1471-2393/11/5
Page 8 of 8
